DE3886506D1 - Avirulente mikroben und deren verwendungen. - Google Patents

Avirulente mikroben und deren verwendungen.

Info

Publication number
DE3886506D1
DE3886506D1 DE88905542T DE3886506T DE3886506D1 DE 3886506 D1 DE3886506 D1 DE 3886506D1 DE 88905542 T DE88905542 T DE 88905542T DE 3886506 T DE3886506 T DE 3886506T DE 3886506 D1 DE3886506 D1 DE 3886506D1
Authority
DE
Germany
Prior art keywords
vertebrate
derivative
invertebrate
immunization
pathogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE88905542T
Other languages
English (en)
Other versions
DE3886506T2 (de
Inventor
Roy Curtiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
MEGA HOLDING
St Louis University
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MEGA HOLDING, St Louis University, Washington University in St Louis WUSTL filed Critical MEGA HOLDING
Publication of DE3886506D1 publication Critical patent/DE3886506D1/de
Application granted granted Critical
Publication of DE3886506T2 publication Critical patent/DE3886506T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE3886506T 1987-06-04 1988-06-01 Avirulente mikroben und deren verwendungen. Expired - Fee Related DE3886506T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5836087A 1987-06-04 1987-06-04
PCT/US1988/001899 WO1988009669A1 (en) 1987-06-04 1988-06-01 Avirulent microbes and uses therefor

Publications (2)

Publication Number Publication Date
DE3886506D1 true DE3886506D1 (de) 1994-02-03
DE3886506T2 DE3886506T2 (de) 1994-05-19

Family

ID=22016346

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3886506T Expired - Fee Related DE3886506T2 (de) 1987-06-04 1988-06-01 Avirulente mikroben und deren verwendungen.

Country Status (15)

Country Link
US (1) US5389368A (de)
EP (1) EP0315682B1 (de)
JP (1) JP2640525B2 (de)
KR (1) KR0139950B1 (de)
CN (1) CN1034553C (de)
AT (1) ATE98870T1 (de)
AU (1) AU623599B2 (de)
CA (1) CA1338957C (de)
DE (1) DE3886506T2 (de)
DK (1) DK175512B1 (de)
IE (1) IE63905B1 (de)
IL (1) IL86583A0 (de)
NZ (1) NZ224884A (de)
WO (1) WO1988009669A1 (de)
ZA (1) ZA883954B (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012086A1 (en) * 1989-03-31 1990-10-18 Washington University Bordetella vaccines
JPH06501847A (ja) * 1990-10-25 1994-03-03 コモンウェルス　サイエンティフィク　アンド　インダストリアルリサーチ　オーガナイゼイション ワクチンベクターとしてのコリネバクテリウム及び関連する生物
US5637303A (en) * 1990-10-25 1997-06-10 Commonwealth Scientific And Industrial Research Organisation Use of a phospholipase D mutant of Corynebacterium pseudotuberculosis for vaccination
DE69133219T2 (de) * 1990-11-09 2004-02-12 Washington University Avirulente salmonella mikroben mit einer mutation in dem cdt gen und ihre verwendung
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
US5599537A (en) * 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5587305A (en) * 1993-12-06 1996-12-24 The United States Of America As Represented By The Department Of Agriculture Pasteurella haemolytica transformants
US6793927B1 (en) 1993-12-06 2004-09-21 The United States Of America As Represented By The Secretary Of The Department Of Agriculture Construction of Pasteurella haemolytica vaccines
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US5925354A (en) * 1995-11-30 1999-07-20 Michigan State University Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
GB9615022D0 (en) * 1996-07-17 1996-09-04 Mini Agriculture & Fisheries Vaccine preparations
US6020144A (en) * 1996-09-12 2000-02-01 Symbiontics, Inc. Sustained delivery device comprising a Leishmania protozoa and methods of making and using the same
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
JP2001519162A (ja) 1997-10-07 2001-10-23 ユニバーシティ・オブ・メリーランド・バイオテクノロジー・インスティチュート 動物細胞にｒｎａを導入して発現させる方法
US6024961A (en) 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
JP2002501748A (ja) 1998-01-31 2002-01-22 ユニバーシティ オブ アーカンソー アレルギー反応を減少させるための方法および試薬
KR100743894B1 (ko) 1998-02-27 2007-07-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신, 면역치료제 및 그의 이용 방법
US6713073B1 (en) * 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
AU772356B2 (en) * 1998-12-04 2004-04-22 Aventis Pasteur Limited Two-step immunization procedure against chlamydia infection
CN1348332A (zh) * 1999-03-03 2002-05-08 宾夕法尼亚大学理事会 疫苗和基因治疗组合物以及其制备和使用方法
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
EP2281834B1 (de) * 1999-04-09 2015-03-04 Zoetis P&U LLC Attenuiertes Bakterium der Familie Pasteurellaceae welches ein mutiertes Virulenzgen aufweist
AU779395B2 (en) * 1999-04-30 2005-01-20 Institut De Recherche Cliniques De Montreal (Ircm) Mutant human CD80 and compositions for and methods of making and using the same
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
ES2260078T3 (es) 2000-04-06 2006-11-01 Seer Pharmaceuticals, Llc. Sistema de administracion microbiana.
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
CA2415187C (en) * 2000-07-14 2013-06-18 David B. Weiner Dna vaccines encoding hiv accessory proteins
AU2002211524B2 (en) 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
US20040137003A1 (en) * 2001-04-30 2004-07-15 Curtiss Iii Roy Regulated antigen delivery system (rads)
WO2003096812A1 (en) * 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
WO2004112706A2 (en) 2003-06-13 2004-12-29 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods for using the same
NZ570709A (en) * 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
EP1691615A2 (de) * 2003-12-09 2006-08-23 Avant Immunotherapeutics, Inc. Oral verabreichte bakterien-lebendimpfstoffe gegen die pest
US20080274140A1 (en) * 2004-11-19 2008-11-06 David B Weiner Vaccines and Methods for Using the Same
WO2007087178A2 (en) * 2006-01-13 2007-08-02 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same
US9259463B2 (en) 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
WO2007106073A2 (en) 2006-03-02 2007-09-20 University Of Massachusetts Modified pathogens for use as vaccines
KR101562888B1 (ko) 2006-07-28 2015-10-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2150616A4 (de) 2007-05-10 2011-07-27 Univ Arizona Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit
WO2008141226A2 (en) * 2007-05-10 2008-11-20 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens
US9040059B2 (en) 2007-10-05 2015-05-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting a protective immune response against C. perfringens
KR101652767B1 (ko) 2008-04-04 2016-08-31 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-28을 이용한 백신 및 면역치료제, 및 그를 사용하는 방법 및 조성물
JP5744719B2 (ja) * 2008-04-04 2015-07-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア チクングニヤウィルスタンパク質の共通配列、これをコードする核酸分子、並びにこれを使用する組成物および方法
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
WO2010045620A1 (en) 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
KR101609233B1 (ko) 2008-10-29 2016-04-05 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개량된 ｈｃｖ 백신 및 이를 이용하는 방법
US8921536B2 (en) 2008-10-29 2014-12-30 The Trustees Of The University Of Pennsylvania HCV vaccines and methods for using the same
CA2653478A1 (en) * 2009-01-23 2010-07-23 Gregg Martin Automated wash system for industrial vehicles
US9050287B2 (en) 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
RU2585216C2 (ru) * 2009-03-23 2016-05-27 Институт Пастор Мутантные полипептиды суаа и производные полипептидов, подходящие для доставки иммуногенных молекул в клетку
US9163219B2 (en) 2009-04-14 2015-10-20 Arizona Board Of Regents On Behalf Of Arizona State University Single expression vector for generation of a virus with a segmented genome
WO2010135563A1 (en) 2009-05-22 2010-11-25 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium and methods of antigen and nucleic acid delivery
US9045742B2 (en) 2009-05-29 2015-06-02 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant Edwardsiella bacterium
KR20120093163A (ko) 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
US9109014B2 (en) 2009-11-02 2015-08-18 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
US9062297B2 (en) 2010-01-13 2015-06-23 The Arizona Board Of Regents For And On Behalf Of Arizona State University Yersinia pestis vaccine
WO2011091291A1 (en) 2010-01-22 2011-07-28 The Arizona Board Of Regents For And On Behalf Of Arizona State University BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011097640A1 (en) 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
WO2011150421A2 (en) 2010-05-28 2011-12-01 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium to decrease tumor growth
US9255283B2 (en) 2010-07-02 2016-02-09 The Arizona Board Of Regents For And On Behalf Of Arizona State University Compositions and methods for bacterial lysis and neutral lipid production
BRPI1003750A2 (pt) 2010-07-22 2012-04-10 Univ Sao Paulo microrganismos recombinantes, métodos de preparação de linhagens vacinais, antìgenos, composições vacinais vetorizadas, seus usos, anticorpos, kit de diagnóstico e métodos de tratamento e/ou profilaxia
EP3909973A3 (de) 2010-11-12 2022-01-26 The Trustees Of The University Of Pennsylvania Konsensus-prostata-antigene, dafür codierende nukleinsäuremoleküle und deren verwendungen
CN102140430B (zh) * 2011-01-13 2013-10-23 河南科技大学 一种不含抗性标记的鼠伤寒沙门氏菌基因缺失突变菌株、疫苗及应用
WO2012106377A2 (en) 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EP2672992B1 (de) 2011-02-11 2020-04-08 The Trustees Of The University Of Pennsylvania Für ein hepatitis-b-virus-kernprotein kodierendes nukleinsäuremolekül und impfstoff damit
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
CN103687625B (zh) 2011-07-11 2017-06-13 艾诺奥医药品有限公司 交叉保护性沙粒病毒疫苗及其使用方法
KR102216962B1 (ko) 2011-10-12 2021-02-18 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 인간 파필로마 바이러스에 대한 백신 및 이것을 사용하는 방법
CN103889460B (zh) 2011-10-24 2016-06-15 宾夕法尼亚大学理事会 改进的hcv疫苗及其使用方法
US9750795B2 (en) 2011-12-12 2017-09-05 The Trustees Of The University Of Pennsylvania Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
KR102101819B1 (ko) 2011-12-12 2020-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
AU2013245950B2 (en) 2012-04-10 2016-04-21 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US9303264B2 (en) 2012-05-18 2016-04-05 The Arizona Board Of Regents For And On Behalf Of Arizona State University Photosynthetic microorganisms expressing thermostable lipase
KR101381793B1 (ko) 2013-02-27 2014-04-07 씨제이제일제당 (주) 신규 박테리오파지 및 이를 포함하는 항균 조성물
EA034056B1 (ru) 2013-03-12 2019-12-23 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Усовершенствованные вакцины против вируса папилломы человека и способы их применения
CN114225019A (zh) 2013-03-15 2022-03-25 宾夕法尼亚大学理事会 癌疫苗及使用其的治疗方法
MX2015011487A (es) 2013-03-15 2016-02-03 Univ Pennsylvania Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas.
US9580718B2 (en) 2013-06-17 2017-02-28 Arizona Board Of Regents On Behalf Of Arizona State University Attenuated live bacteria with increased acid resistance and methods of use thereof
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11235044B2 (en) 2017-12-13 2022-02-01 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting MUC16 and uses thereof
ES2938900T3 (es) 2017-12-13 2023-04-17 Inovio Pharmaceuticals Inc Vacunas contra el cáncer dirigidas al PRAME y usos de las mismas
EP3723810A4 (de) 2017-12-13 2022-02-23 Inovio Pharmaceuticals, Inc. Gegen mesothelin gerichtete krebsvakzine und deren verwendungen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239749A (en) 1964-07-06 1966-03-08 Gen Electric Transformer system
US3975517A (en) 1972-05-25 1976-08-17 Canadian Patents And Development Limited Enteric disease vaccine
US3931398A (en) 1973-06-20 1976-01-06 Colgate-Palmolive Company Method for local immunization against dental caries
US4203971A (en) 1978-03-23 1980-05-20 Government Of The United States Neisseria gonorrhoeae vaccine
US4250262A (en) 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US4550081A (en) 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4888170A (en) * 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines

Also Published As

Publication number Publication date
EP0315682B1 (de) 1993-12-22
DE3886506T2 (de) 1994-05-19
WO1988009669A1 (en) 1988-12-15
DK52789A (da) 1989-02-03
KR0139950B1 (ko) 1998-06-01
IE881646L (en) 1988-12-04
DK175512B1 (da) 2004-11-15
IL86583A0 (en) 1988-11-15
AU623599B2 (en) 1992-05-21
CN1034553C (zh) 1997-04-16
CA1338957C (en) 1997-03-04
ATE98870T1 (de) 1994-01-15
KR890701125A (ko) 1989-12-19
NZ224884A (en) 1990-12-21
EP0315682A4 (de) 1989-11-14
AU1955088A (en) 1989-01-04
DK52789D0 (da) 1989-02-03
EP0315682A1 (de) 1989-05-17
CN1030018A (zh) 1989-01-04
JP2640525B2 (ja) 1997-08-13
IE63905B1 (en) 1995-06-14
ZA883954B (en) 1989-02-22
US5389368A (en) 1995-02-14
JPH01503442A (ja) 1989-11-22

Similar Documents

Publication Publication Date Title
DE3886506D1 (de) Avirulente mikroben und deren verwendungen.
Hanff et al. Humoral immune response in human syphilis to polypeptides of Treponema pallidum.
ATE127345T1 (de) Stressproteine und verwendungen dafür.
ES2063965T3 (es) Vacunas para haemophilus influenzae no tipificable.
DE68927348T2 (de) Künstlicher impfstoff gegen aids-virus
MX9204685A (es) Secuencia de adn que codifica una proteina superficial externa (ospa) o derivado de la misma composicion de vacuna qe comprende tal proteina.
ATE277633T1 (de) Präparate und verfahren zum auslösen von ctl- immunität
GB2255093A (en) Hiv-1 core protein fragments
HK1080506A1 (en) Fusion proteins of mycobacterium tuberculosis
TR199801722T2 (xx) Peptit imm�nojenler.
NL300185I1 (nl) Acellulair vaccin.
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
ATE157258T1 (de) Zubereitungen und behandlungen von pneumonia in tieren
FI955150A0 (fi) OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistamiseksi
DK0556333T3 (da) Avirulente Salmonella mikrober, der omfatter en mutation i cdt genet, og anvendelser deraf
EP0498804A4 (en) A method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
HUP0102235A1 (hu) Moraxella catarrhalis BASBO27-fehérjék és -gének, továbbá antigének, ellenanyagok és alkalmazások
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
ATE175357T1 (de) Empfängnisverhütender impfstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: WASHINGTON UNIVERSITY, ST.LOUIS, MO., US

8328 Change in the person/name/address of the agent

Free format text: DR. A. V. FUENER, DIPL.-ING. D. EBBINGHAUS, DR. ING. D. FINCK, DIPL.-ING. C. HANO, PATENTANWAELTE, 81541 MUENCHEN

8339 Ceased/non-payment of the annual fee